ClinicalTrials.gg
Active, not recruitingNCT07213583Updated Oct 7, 2026

Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

A Phase 2 interventional study of ALXN2220 in Amyloid Transthyretin Cardiomyopathy, sponsored by Neurimmune AG. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Neurimmune AG · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies in Amyloidosis with a site in France — 17 open to participants now, 22 under way, 8 of them phase 3. Amyloidosis · France.

Planned enrollment
42nd of 48
35 · median 145
Started
2025
with 3 others
Phase 2
10 of 56
2 open now
Primary completion
2026-10
later than 4 of 21 live
Registered
52nd of 56
by date
Lead sponsor
2 of 56
Neurimmune AG

Among the 56 studies in Amyloidosis with a site in France, this one is the 42nd largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 4 of the 21 other live ones, and was the 52nd registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

17 of the 56 studies in Amyloidosis with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Amyloidosis with a site in France, or all of them as a file.
02

Study summary

This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.

Read the detailed description

This is a Phase 2, single arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in the patient population of previous participants in Study NI006-101.

The study will also explore changes in cardiac structure and function, and clinical function of this dosing regimen, as well as changes in cardiac amyloid load, structure and function during the treatment-pause since conclusion of Study NI006-101. The study consists of a Screening Period and a 48 week Active Treatment Period.

03

Conditions studied

  • Amyloid Transthyretin Cardiomyopathy

Browse trials for

Keywords

  • Amyloid Depleter
  • ALXN2220
  • Transthyretin Amyloid Cardiomyopathy
  • Transthyretin amyloid (ATTR)
  • Transthyretin (TTR)
  • Amyloidosis
  • ATTR-CM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have received at least one dose of ALXN2220 in Study NI006-101

Exclusion criteria

Exclusion Criteria:

  • Suspected or known intolerance/allergy to proteins or any components of the study drug
  • Treatment or study discontinuation in Study NI006-101 due to a treatment-related adverse event that was serious, severe or life-threatening (on (CTCAE) scale)
  • Any new or uncontrolled condition after completion of Study NI006-101 that could make the participant unsuitable for participation in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    ALXN2220

    Participants will receive ALXN2220 via intravenous (IV) infusion during the Active Treatment Period

    Drug: ALXN2220

Interventions

  • Participants will receive ALXN2220 via IV infusion.

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 48 in ECV measured by cMRI

    Time frame: Baseline, Week 48

  2. Change from Baseline to Week 48 in Heart Retention/Whole Body Retention measured by scintigraphy

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Incidence of TEAEs, including serious TEAEs

    Time frame: From Baseline up to Week 48

  2. ALXN2220 serum concentrations

    Time frame: From Baseline up to Week 48

  3. Incidence of Anti-Drug Antibodies

    Time frame: From Baseline up to Week 48

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: Yes — Neurimmune has a public commitment to allow requests for study data and will be supplying protocol, results and plain language summaries.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Oct 2026, 14 months after the start.

Of 24 phase 2 interventional studies under Amyloidosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 64. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Oct 9, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07213583
Lead sponsor
Neurimmune AG
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Aug 28, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Oct 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cliramitug

Start the discussion